Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.45 |
| ▸ | MEN1 | O00255 | 5/20 | 0.45 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | ALPG | P10696 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL3042035 | 0.98 | ALDH1A1 (0.51) | ALDH1A1POLBRECQLKDM4EKMT2A | |
| Hydrochloric Acid SCHEMBL7759133 | 0.98 | KDM4E (0.49) | ALDH1A1POLBRECQLKDM4EKMT2A | |
| SCHEMBL4255418 | 0.84 | KMT2A (0.59) | ALDH1A1POLBRECQLKDM4EKMT2A | |
| Bromide SCHEMBL2956995 | 0.83 | KMT2A (0.62) | ALDH1A1POLBRECQLKDM4EKMT2A | |
| Hydrochloric Acid SCHEMBL3847661 | 0.78 | ALDH1A1 (0.47) | ALDH1A1POLBRECQLKDM4EKMT2A | |
| SCHEMBL13394254 | 0.75 | KMT2A (0.70) | ALDH1A1POLBRECQLKDM4EKMT2A | |
| Alagebrium SCHEMBL1820212 | 0.74 | KMT2A (0.71) | ALDH1A1POLBRECQLKDM4EKMT2A | |
| SCHEMBL3960921 | 0.74 | KMT2A (0.44) | ALDH1A1POLBRECQLKDM4EKMT2A | |
| Bromide SCHEMBL1645919 | 0.73 | KMT2A (0.73) | ALDH1A1POLBRECQLKDM4EKMT2A | |
| Alagebrium SCHEMBL225618 | 0.73 | KMT2A (0.69) | ALDH1A1POLBRECQLKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384625-B2 | Method and composition for rejuvenating hair, nails, tissues, cells and organs by ex-vivo or immersive treatment | FARINGTON PHARMACEUTICALS, LLC (US) | 2008-06-10 | — | — | US | claimed |
| US-6713050-B2 | A THIAZOLIUM COMPOUND FOR TREATMENT OF HAIR, NAIL, EX-VIVO ORGAN, TISSUE OR CELLS BY IMPROVING THE DEFORMABILITY AND DIFFUSION COEFFICIENT OF HAIR, NAILS, TISSUES, CELLS, AND ORGANS IN HUMAN AND ANIMALS | FARRINGTON PHARMACEUTICALS, INC. | 2004-03-30 | — | — | US | claimed |
| US-RE38330-E1 | Preventing and reversing advanced glycosylation endproducts | ALTEON INC. | 2003-11-25 | — | — | US | claimed |
| EP-0808163-B1 | USE OF THIAZOLIUM COMPOUNDS FOR PREVENTING AND REVERSING THE FORMATION OF ADVANCED GLYCOSYLATION ENDPRODUCTS | ALTEON INC (US) | 2003-07-23 | — | — | EP | claimed |
| US-20020182165-A1 | Method and composition for rejuvenating hair, nails, tissues, cells and organs by ex-vivo or immersive treatment | FARRINGTON PHARMACEUTICALS, LLC | 2002-12-05 | — | — | US | claimed |
| US-6440749-B1 | ADMINISTERING A THIAZOLE COMPOUND | ALTEON. INC. | 2002-08-27 | — | — | US | claimed |
| WO-2002056836-A2 | METHOD AND COMPOSITION FOR REJUVENATING HAIR, NAILS, TISSUES, CELLS AND ORGANS BY EX-VIVO OR IMMERSIVE TREATMENT | FARRINGTON PHARMACEUTICALS, LLC (US) | 2002-07-25 | — | — | WO | claimed |
| US-6007865-A | FOR INHIBITING AND REVERSING NONENZYMATIC CROSS-LINKING (PROTEIN AGING), TREATING KIDNEY DAMAGE AND TREATING COMPLICATIONS OF DIABETES, PREVENTING FOOD SPOILAGE | ALTEON INC. | 1999-12-28 | — | — | US | claimed |
| US-9622469-B2 | Crosslink breakers for preservation of biological substances | SPIEGEL DAVID (US) | 2017-04-18 | — | — | US | disclosed |
| US-20150099260-A1 | Crosslink Breakers for Preservation of Biological Substances | SPIEGEL DAVID (US) | 2015-04-09 | — | — | US | disclosed |
| US-RE38330-E1 | Preventing and reversing advanced glycosylation endproducts | ALTEON INC. | 2003-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020182165-A1 | Method and composition for rejuvenating hair, nails, tissues, cells and organs by ex-vivo or immersive treatment | COL1A1, KRT18, COL2A1 | ALDH1A1 825/4885POLB 417/4885RECQL 482/4885 |
| US-20150099260-A1 | Crosslink Breakers for Preservation of Biological Substances | AGER, LMNA, SSB | ALDH1A1 555/4885POLB 575/4885RECQL 2411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.